We have located links that may give you full text access.
Determination of A Novel Antifibrotic Small Molecule GDC-3280 in Human Plasma and Urine by Liquid Chromatography Tandem Mass Spectrometry to Support Its First-in-human Clinical Trial.
Biomedical Chromatography : BMC 2019 January 8
A specific and robust LC-MS/MS method was developed and validated for the quantitative determination of GDC-3280 in human plasma and urine. The nonspecific binding associated with urine samples was overcome by the addition of CHAPS. The sample volume was 25 μL for either matrix, and supported liquid extraction was employed for analyte extraction. d6-GDC-3280 was used as the internal standard. Linear standard curves (R2 >0.9956) were established from 5.00 to 5000 ng/mL in both matrices with quantitation extended to 50,000 ng/mL through dilution. In plasma matrix, the precision (%RSD) ranged from 1.5% to 9.9% (intra-run) and from 2.4% to 7.2% (inter-run); the accuracy (%RE) ranged from 96.1% to 107% (intra-run) and from 96.7% to 104% (inter-run). Similarly, in urine the precision was 1.5% to 6.2% (intra-run) and 1.9% to 6.1% (inter-run); the accuracy was 83,1% to 99.3% (intra-run) and 87.1% to 98.3% (inter-run). Good recovery (>94%) and negligible matrix effect were achieved in both matrices. Long-term matrix stability was established for at least 703 days in plasma and 477 days in urine. Benchtop stability of 25 hrs and 5 freeze-thaw cycles were also confirmed in both matrices. The method was successfully implemented in GDC-3280's FIH trial for assessing its pharmacokinetic profiles.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app